NCT03996434 - Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

November 10, 2019

Study Completion Date

November 20, 2019

Conditions

Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Gonadotropin

withholding gonadotropin administration for at least 24 hours

DRUG

Antagonist

Cetrorelix acetate 0.25 mg

Trial Locations (2)

Alazahr University, Cairo

Assisted Reproduction Unit International Islamic Centre for Population Studies and Research, Al-Azhar University, Cairo